AstraZeneca, M.D. Anderson sign pain research deal

AstraZeneca and the University of Texas M. D. Anderson Cancer Center are teaming up to study pain caused by cancer chemotherapy, a side effect that often interferes with patients' ability to stick to the treatments. AstraZeneca and M. D. Anderson will attempt to identify the difference between patients who experience little pain and those with severe pain; understanding these variations could present new drug targets. Financial details of the partnership were not disclosed.

According to the press release, "[t]his is the third of several planned new alliances by AstraZeneca with leading academic and research institutions to address unmet medical needs...including Alzheimer's disease, chronic pain and psychiatric illnesses."

- see this release for more

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.